Insulin Resistance and Polycystic Ovarian Syndrome [2007][PDF]-KingMax

TITLE

© Contemporary Endocrinology
2007

Insulin Resistance and Polycystic Ovarian Syndrome
Pathogenesis, Evaluation, and Treatment

Autors

Editors
Evanthia Diamanti-Kandarakis MD, PhD (1)
Endocrine Section of First Department of Internal Medicine, Athens University School of Medicine

John E. Nestler MD (2)
Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University

Dimitrios Panidis MD, PhD (3)
Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki

Renato Pasquali MD (4)
Endocrinology Unit, Department of Internal Medicine and Gastroenterology and C.R.B.A., S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna

ISBN

Print ISBN
978-1-58829-763-1

Online ISBN
978-1-59745-310-3

FORMAT

(PDF, 67057 KB)
Number of Pages: XVI+475

About

Despite dizzyingly fast-paced advances over the past two decades, even the definition of Polycystic Ovarian Syndrome (PCOS) remains in dispute. Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment highlights the recent transition of PCOS from an infertility disorder with a diagnosis based on ovarian tissue histology to a more complex clinical entity, a metabolic disorder in which insulin resistance plays a central role. With an expert panel of authors, each chapter provides an up-to-date and balanced overview of PCOS, paying special attention to the central role of insulin resistance in the syndrome’s pathogenesis and in the management of its reproductive and metabolic abnormalities.
Comprehensive and thought-provoking, Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment is an invaluable resource for endocrinologists, gynecologists, and internists eager to learn more about this controversial and challenging disease

Table of Contents

(33 chapters)
1) Evaluation for Insulin Resistance and Comorbidities Related to Insulin Resistance in Polycystic Ovary Syndrome
2) Fat Distribution and Adipose Products in Polycystic Ovary Syndrome
3) Treatment of Infertility in Polycystic Ovary Syndrome
4) Imaging Studies in Polycystic Ovary Syndrome
5) Genes Related to Metabolic Abnormalities or Insulin Resistance in Polycystic Ovary Syndrome
6) Anti-Androgens
7) Lipid Abnormalities in Polycystic Ovary Syndrome
8) Serine Phosphorylation, Insulin Resistance, and the Regulation of Androgen Synthesis
9) Chronic Treatment of Polycystic Ovary Syndrome
10) Insulin-Sensitizing Drugs for the Treatment of Infertility in Polycystic Ovary Syndrome
11) Diet and Lifestyle Factors in the Etiology and Management of Polycystic Ovary Syndrome
12) Adrenarche
13) Cardiovascular Disease and Inflammation
14) Surgery and Laser Diathermy
15) Late Pregnancy Complications in Polycystic Ovary Syndrome
16) Glucose Intolerance
17) Hormonal and Biochemical Evaluation of Polycystic Ovary Syndrome
18) Endometrial Carcinoma in Polycystic Ovary Syndrome
19) Statins, Oxidative Stress, and Polycystic Ovary Syndrome
20) Glucose Intolerance in Polycystic Ovary Syndrome
21) Polycystic Ovary Syndrome
22) Anovulation in Polycystic Ovary Syndrome
23) Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome
24) “Secondary” Polycystic Ovary Syndrome
25) Long-Term Sequelae of Polycystic Ovary Syndrome
26) The Insulin Resistance of Polycystic Ovary Syndrome
27) Therapeutic Aspects of Polycystic Ovary Syndrome in Adolescence
28) Lifestyle Intervention in Polycystic Ovarian Syndrome
29) Involvement of the Endocannabinoid System in Metabolism and Fertility
30) Insulin Resistance
31) Clinical Evaluation of Polycystic Ovary Syndrome
32) Pharmaceutical Intervention in Metabolic and Cardiovascular risk Factors in Polycystic Ovary Syndrome
33) Insulin Resistance and Early Pregnancy Loss in Polycystic Ovary Syndrome